Following closely on the heels of the very recent FDA approval of Rubraca (rucaparib) for advanced prostate cancer in men with a BRCA1/2 mutation, we now have a second PARP-inhibitor approved by the FDA. This one has the trade name of Lynparza and generic name of olaparib. This approval was based on the recently published Phase 3 clinical trial in the New England Journal of Medicine. Whereas Rubraca was approved for men who previously failed both chemotherapy and a second line antiandrogen (such as Zytiga, Xtandi, Erleada, etc.), Lynparza is approved even if the patient hasn’t had any chemotherapy.
You can read the full PCF press release here: https://www.pcf.org/blog/breaking-news-fda-approves-olaparib-for-treatment-of-advanced-prostate-cancer/